But until the research catches up, and regulation does, too, the risks belong entirely to the user and those risks are not completely theoretical
Accessed October Ukhanova M, Wozny JS, Truong CN, Ghosh L, Krause TM (2025) Trends in glucagon-like peptide 1 receptor agonist prescribing patterns
Nivn, L
18% (semaglutide) 30% Weight Loss: 21% (CagriSema) vs
For those considering the longer view, understanding how long you stay on semaglutide and what withdrawal symptoms might occur when stopping helps with treatment planning
Semaglutide under the brand names Ozempic and Wegovy, tirzepatide under the names Mounjaro and Zepbound, and other medications in this class have demonstrated meaningful results for weight management and blood sugar control that go beyond what most previous treatment options could offer